B
BlossomHill Therapeutics Inc D
D
BLSM
16.850
USD
-0.28
(-1.72%)
Post Trading·15.950USD-0.900(-5.34%)
حجم التداول
1,134
الربح لكل سهم
0
العائد الربحي
-
P/E
-5
حجم السوق
490,017,546
العنوان: BlossomHill Therapeutics Inc
القطاع: الرعاية الصحية
الصناعة: Biotechnology
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.